TY - JOUR
T1 - Association of elevated plasminogen activator inhibitor 1 levels with diminished lung function in patients with asthma
AU - Cho, Seong
AU - Kang, Joseph
AU - Lyttle, Christopher
AU - Harris, Kathleen
AU - Daley, Brendan
AU - Grammer, Leslie
AU - Avila, Pedro
AU - Kumar, Rajesh
AU - Schleimer, Robert
N1 - Funding Information:
Funding Sources: This study was supported by a American Academy of Allergy, Asthma and Immunology/GlaxoSmithKline Fellows Career Development Award , National Heart, Lung, and Blood Institute grant 1-U01 HL 72496-1 , National Heart, Lung, and Blood Institute grant R01 HL068546 , and the Bazley Trust .
PY - 2011/5
Y1 - 2011/5
N2 - Background: We previously reported that plasminogen activator inhibitor 1 (PAI-1) was upregulated in human asthmatic airways and promotes airway fibrosis in an allergen-challenged murine model of asthma. Objectives: To examine whether elevated plasma levels of PAI-1 are associated with poor lung function in asthmatic patients. Methods: Five hundred nineteen adults were eligible for the study, and ultimately 353 adults were enrolled and completed the baseline protocol between January 24, 2004, and July 30, 2005. Of these, 231 adults with asthma from the Chicago Initiative to Raise Asthma Health Equity study were randomly selected and the plasma levels of PAI-1 were measured by enzyme-linked immunosorbent assay. Asthma burden, medication, smoking status, and body mass index (BMI) were obtained by history and spirometry was performed. A multivariate regression analysis was performed to evaluate the association of PAI-1 levels and lung function and the potential determinant variables that were associated with PAI-1. Results: We found associations between PAI-1 and BMI (β = 0.606, P = .002), smoking (β = 7.526, P = .001), and African American race (β = -9.061, P = .01). Obese patients showed a significant increase in PAI-1, and current smokers demonstrated higher levels of PAI-1 compared with nonsmokers. When we evaluated the associations between lung function parameters and PAI-1, we found that PAI-1 was negatively associated with forced vital capacity (FVC) (β = -0.098, P = .011) but not with forced expiratory volume in 1 second (FEV 1) or the FEV 1/FVC ratio. There was a negative association between BMI and FVC, and PAI-1 may mediate some of this association. Conclusions: This study suggests a significant association between PAI-1 and lung function in patients with asthma. The effect of obesity on FVC may in part be mediated by PAI-1.
AB - Background: We previously reported that plasminogen activator inhibitor 1 (PAI-1) was upregulated in human asthmatic airways and promotes airway fibrosis in an allergen-challenged murine model of asthma. Objectives: To examine whether elevated plasma levels of PAI-1 are associated with poor lung function in asthmatic patients. Methods: Five hundred nineteen adults were eligible for the study, and ultimately 353 adults were enrolled and completed the baseline protocol between January 24, 2004, and July 30, 2005. Of these, 231 adults with asthma from the Chicago Initiative to Raise Asthma Health Equity study were randomly selected and the plasma levels of PAI-1 were measured by enzyme-linked immunosorbent assay. Asthma burden, medication, smoking status, and body mass index (BMI) were obtained by history and spirometry was performed. A multivariate regression analysis was performed to evaluate the association of PAI-1 levels and lung function and the potential determinant variables that were associated with PAI-1. Results: We found associations between PAI-1 and BMI (β = 0.606, P = .002), smoking (β = 7.526, P = .001), and African American race (β = -9.061, P = .01). Obese patients showed a significant increase in PAI-1, and current smokers demonstrated higher levels of PAI-1 compared with nonsmokers. When we evaluated the associations between lung function parameters and PAI-1, we found that PAI-1 was negatively associated with forced vital capacity (FVC) (β = -0.098, P = .011) but not with forced expiratory volume in 1 second (FEV 1) or the FEV 1/FVC ratio. There was a negative association between BMI and FVC, and PAI-1 may mediate some of this association. Conclusions: This study suggests a significant association between PAI-1 and lung function in patients with asthma. The effect of obesity on FVC may in part be mediated by PAI-1.
UR - http://www.scopus.com/inward/record.url?scp=79955584637&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79955584637&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2010.12.021
DO - 10.1016/j.anai.2010.12.021
M3 - Article
C2 - 21530867
AN - SCOPUS:79955584637
VL - 106
SP - 371
EP - 377
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
SN - 1081-1206
IS - 5
ER -
